Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Juno Therapeutics (JUNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval

Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.

CELG : 121.33 (-10.76%)
NVS : 85.74 (-0.49%)
GILD : 81.21 (-0.47%)
JUNO : 43.71 (+0.71%)
Trianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform

Trianni, Inc. ("TRIANNI") today announced that Juno Therapeutics (NASDAQ: JUNO) has entered into a license agreement for The Trianni Mouse(TM), a best-in-class monoclonal antibody discovery platform. Juno...

JUNO : 43.71 (+0.71%)
Breakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma

If you want a Stock Review on BCRX, CELG, JUNO, or LXRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Research reports have been issued by DailyStockTracker.com...

LXRX : 11.16 (-1.59%)
CELG : 121.33 (-10.76%)
BCRX : 4.80 (-5.88%)
CELGZ : 1.51 (+6.34%)
JUNO : 43.71 (+0.71%)
New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bed Bath and Beyond Inc. (Nasdaq:BBBY),...

FINL : 10.57 (+4.14%)
MAT : 15.97 (+1.01%)
BBBY : 21.47 (+1.27%)
EXEL : 27.17 (-1.06%)
GRMN : 55.80 (+0.63%)
JUNO : 43.71 (+0.71%)
Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

The "CAR-T r/r CLL Global Market Forecast" report has been added to Research and Markets' offering.

NVS : 85.74 (-0.49%)
KITE : 179.99 (+0.11%)
JUNO : 43.71 (+0.71%)
Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno Therapeutics, Inc., LendingClub Corporation, MiMedx Group, Inc., Ooma, Inc. and SCANA Corporation

Foundation Medicine, Inc. (FMI)

OOMA : 10.60 (+1.44%)
MDXG : 13.90 (+0.51%)
FMI : 41.10 (-1.32%)
SCG : 49.04 (+0.80%)
LC : 6.00 (+0.33%)
HIIQ : 21.50 (-1.15%)
JUNO : 43.71 (+0.71%)
Lifshitz & Miller LLP Announces Investigation of Foundation Medicine, Inc., Health Insurance Innovations, Inc., Juno Therapeutics, Inc., LendingClub Corporation, MiMedx Group, Inc., Ooma, Inc. and SCANA Corporation

NEW YORK , Oct. 3, 2017 /PRNewswire/ --

OOMA : 10.60 (+1.44%)
MDXG : 13.90 (+0.51%)
FMI : 41.10 (-1.32%)
SCG : 49.04 (+0.80%)
LC : 6.00 (+0.33%)
HIIQ : 21.50 (-1.15%)
JUNO : 43.71 (+0.71%)
Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on...

CELGZ : 1.51 (+6.34%)
JUNO : 43.71 (+0.71%)
Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

KERX : 6.50 (+0.62%)
ABEO : 19.00 (+7.04%)
JNJ : 142.40 (+0.25%)
JUNO : 43.71 (+0.71%)
Robbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juno Therapeutics, Inc. (NASDAQGS: JUNO) breached their fiduciary duty to shareholders...

JUNO : 43.71 (+0.71%)
Juno Tenders $250M Follow-on Public Offering of Common Stock

Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.

CELG : 121.33 (-10.76%)
AZN : 34.62 (-0.26%)
ADRO : 9.20 (-0.27%)
JUNO : 43.71 (+0.71%)
Today's Research Reports on Stocks to Watch: Juno Therapeutics and Biogen

NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Biogen tumbled on Thursday after receiving a downgrade from Raymond James that took it down two notches from "strong buy" to "market perform."...

JUNO : 43.71 (+0.71%)
BIIB : 338.10 (-1.26%)
Juno Therapeutics Prices $250 Million Follow-on Offering

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on...

CELGZ : 1.51 (+6.34%)
JUNO : 43.71 (+0.71%)
Juno Therapeutics Opens New Headquarters and Research Center

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research...

JUNO : 43.71 (+0.71%)
Juno Therapeutics Launches Follow-on Offering

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the launch of a proposed follow-on...

MS : 50.68 (+1.79%)
JUNO : 43.71 (+0.71%)
Here's Why These 3 Biotech Stocks Might Stop Rallying

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

KERX : 6.50 (+0.62%)
ABEO : 19.00 (+7.04%)
JNJ : 142.40 (+0.25%)
JUNO : 43.71 (+0.71%)
Stull, Stull & Brody Announces Lawsuit Against Certain Officers and Directors of Juno Therapeutics, Inc. (NASDAQ: JUNO)

Stull, Stull & Brody announces that a lawsuit was commenced in the United States District Court for the Western District of Washington against certain executive officers and members of the Board of Directors...

JUNO : 43.71 (+0.71%)
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus

With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.

CELG : 121.33 (-10.76%)
BLUE : 142.55 (+2.22%)
NVS : 85.74 (-0.49%)
ZIOP : 5.40 (-4.09%)
GILD : 81.21 (-0.47%)
KITE : 179.99 (+0.11%)
JUNO : 43.71 (+0.71%)
Technical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma

If you want a Stock Review on ZIOP, ZSAN, JUNO, or LXRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. The Medical sector, which includes both pharmaceutical/Biotech...

LXRX : 11.16 (-1.59%)
ZIOP : 5.40 (-4.09%)
ZSAN : 0.85 (unch)
JUNO : 43.71 (+0.71%)
Biotech Stocks Move Higher on New Clinical Trial Developments and Ground-breaking Collaborations

As biotech and pharma stocks power through new resistance levels in the markets, the sector is being fueled by the latest positive FDA developments and notable clinical trial advancements that appear to...

XOMA : 22.65 (-2.66%)
IOVA : 7.22 (unch)
INSM : 27.55 (+2.11%)
JUNO : 43.71 (+0.71%)
MBRX : 2.18 (-1.36%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 best NASDAQ 100 stocks that had the highest return in the past year, had consistent price appreciation and still looked like they had room to go.
AMAT +0.76 , NVDA -0.90 , ADSK +1.52 , MU +0.19 , LRCX +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.21%) this morning are up +0.23% at a new record high on optimism that the Trump administration will be able to enact its tax reform plans after the Senate adopted a fiscal 2018 budget... Read More

Chart of the Day

Chart of the Day

LimeLight Networks (LLNW) is the Barchart Chart of the Day.  The Internet company has a Trend Spotter buy signal, a Weighted Alpha of 18.33+ and gained 149.71% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended Friday with most contracts 3 1/2 to 4 1/2 cents lower. The USDA announced private export sales of 125,000 MT of corn to Unknown Destinations, with an additional 120,000 MT to Spain for 17/18 delivery through their daily reporting s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart